Neuromyelitis Optica Spectrum Disorder (NMOSD) Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Aeterna Zentaris, Shanghai Pharma, Guangzhou Lupeng Pharma, Harbour BioMed

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Neuromyelitis Optica Spectrum Disorder pipeline constitutes 7+ key companies continuously working towards developing 8+ Neuromyelitis Optica Spectrum Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Neuromyelitis Optica Spectrum Disorder Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neuromyelitis Optica Spectrum Disorder Market.

The Neuromyelitis Optica Spectrum Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Neuromyelitis Optica Spectrum Disorder Pipeline Report: https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Neuromyelitis Optica Spectrum Disorder treatment therapies with a considerable amount of success over the years.
• Neuromyelitis Optica Spectrum Disorder companies working in the treatment market are ENDECE, Aeterna Zentaris, Shanghai Pharmaceuticals, Guangzhou Lupeng Pharmaceutical, Harbour BioMed, Reistone Biopharma, RemeGen, Alexion Pharmaceuticals, and others, are developing therapies for the Neuromyelitis Optica Spectrum Disorder treatment
• Emerging Neuromyelitis Optica Spectrum Disorder therapies in the different phases of clinical trials are- NDC-1308, AIM Biologicals, B001, LP-168, HBM9161, SHR1459, Telitacicept, Ravulizumab, and others are expected to have a significant impact on the Neuromyelitis Optica Spectrum Disorder market in the coming years.
• In October 2022, ULTOMIRIS® (ravulizumab-cwvz), compared to the external placebo arm from the pivotal SOLIRIS®PREVENT clinical trial, significantly decreased relapse risk in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+)neuromyelitis optica spectrum disorder (NMOSD), according to detailed encouraging results from the Phase III CHAMPION-NMOSD trial.
• In June 2022, To assess the efficacy, pharmacokinetics, pharmacodynamics, and safety of ravulizumab in children and adolescents with aquaporin-4 antibody positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD), Alexion Pharmaceuticals started a Phase II/III, open-label, historical-controlled, single-arm, multicenter study.
• In June 2022: UPLIZNA was also given the go-ahead by the Brazilian Health Regulatory Agency (ANVISA) as a monotherapy for the treatment of adult NMOSD patients who test positive for the AQP4-IgG biomarker.
• In May 2022: The European Commission has approved the use of UPLIZNA, a medication created by Horizon Therapeutics, as a monotherapy for treating adult patients with neuromyelitis optica spectrum disease (NMOSD). No matter if a patient's AQP4-IgG test results are positive or negative, this approval is valid for all adult NMOSD patients.
• In May 2022, According to ULTOMIRIS® (ravulizumab-cwvz) Phase III study results in adults with neuromyelitis optica spectrum condition, Alexion Pharmaceuticals reported.

Neuromyelitis Optica Spectrum Disorder Overview
NMOSD, often referred to as Devic disease, is a chronic condition of the brain and spinal cord characterized by inflammation of the optic nerve (optic neuritis) and spinal cord (myelitis). NMOSD affects between 0.05-0.40 and 0.52-4.4 people per 100,000, respectively, in terms of incidence and prevalence.

Get a Free Sample PDF Report to know more about Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Neuromyelitis Optica Spectrum Disorder Drugs Under Different Phases of Clinical Development Include:
• NDC-1308: ENDECE
• AIM Biologicals: Aeterna Zentaris
• B001: Shanghai Pharmaceuticals Holding Co., Ltd.
• LP-168: Guangzhou Lupeng Pharmaceutical Company LTD.
• HBM9161: Harbour BioMed
• SHR1459: Reistone Biopharma
• Telitacicept: RemeGen
• Ravulizumab: Alexion Pharmaceuticals

Neuromyelitis Optica Spectrum Disorder Route of Administration
Neuromyelitis Optica Spectrum Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Neuromyelitis Optica Spectrum Disorder Molecule Type
Neuromyelitis Optica Spectrum Disorder Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutics Assessment
• Neuromyelitis Optica Spectrum Disorder Assessment by Product Type
• Neuromyelitis Optica Spectrum Disorder By Stage and Product Type
• Neuromyelitis Optica Spectrum Disorder Assessment by Route of Administration
• Neuromyelitis Optica Spectrum Disorder By Stage and Route of Administration
• Neuromyelitis Optica Spectrum Disorder Assessment by Molecule Type
• Neuromyelitis Optica Spectrum Disorder by Stage and Molecule Type

DelveInsight's Neuromyelitis Optica Spectrum Disorder Report covers around 5+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Neuromyelitis Optica Spectrum Disorder product details are provided in the report. Download the Neuromyelitis Optica Spectrum Disorder pipeline report to learn more about the emerging Neuromyelitis Optica Spectrum Disorder therapies at:
https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Neuromyelitis Optica Spectrum Disorder Therapeutics Market include:
Key companies developing therapies for Neuromyelitis Optica Spectrum Disorder are - Hoffmann-La Roche Ltd, Horizon Therapeutics plc, TG Therapeutics, Opexa Therapeutics, Mitsubishi Tanabe, AstraZeneca, Harbour BioMed, RemeGen, Teva Pharmaceutical, TG Therapeutics, Opexa Therapeutics, and others.

Neuromyelitis Optica Spectrum Disorder Pipeline Analysis:
The Neuromyelitis Optica Spectrum Disorder pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Neuromyelitis Optica Spectrum Disorder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuromyelitis Optica Spectrum Disorder Treatment.
• Neuromyelitis Optica Spectrum Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Neuromyelitis Optica Spectrum Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuromyelitis Optica Spectrum Disorder market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Neuromyelitis Optica Spectrum Disorder drugs and therapies-
https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Neuromyelitis Optica Spectrum Disorder Pipeline Market Drivers
• Increase in NMOSD prevalence, rising awareness among general population about NMOSD• Emergence of novel therapies are some of the important factors that are fueling the Neuromyelitis Optica Spectrum Disorder Market.

Neuromyelitis Optica Spectrum Disorder Pipeline Market Barriers
• However, dearth of skilled professionals and lack of healthcare infrastructure in developing economies, high costs for NMOSD treatment and other factors are creating obstacles in the Neuromyelitis Optica Spectrum Disorder Market growth.

Scope of Neuromyelitis Optica Spectrum Disorder Pipeline Drug Insight
• Coverage: Global
• Key Neuromyelitis Optica Spectrum Disorder Companies: ENDECE, Aeterna Zentaris, Shanghai Pharmaceuticals, Guangzhou Lupeng Pharmaceutical, Harbour BioMed, Reistone Biopharma, RemeGen, Alexion Pharmaceuticals, and others
• Key Neuromyelitis Optica Spectrum Disorder Therapies: NDC-1308, AIM Biologicals, B001, LP-168, HBM9161, SHR1459, Telitacicept, Ravulizumab, and others
• Neuromyelitis Optica Spectrum Disorder Therapeutic Assessment: Neuromyelitis Optica Spectrum Disorder current marketed and Neuromyelitis Optica Spectrum Disorder emerging therapies
• Neuromyelitis Optica Spectrum Disorder Market Dynamics: Neuromyelitis Optica Spectrum Disorder market drivers and Neuromyelitis Optica Spectrum Disorder market barriers

Request for Sample PDF Report for Neuromyelitis Optica Spectrum Disorder Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Neuromyelitis Optica Spectrum Disorder Report Introduction
2. Neuromyelitis Optica Spectrum Disorder Executive Summary
3. Neuromyelitis Optica Spectrum Disorder Overview
4. Neuromyelitis Optica Spectrum Disorder- Analytical Perspective In-depth Commercial Assessment
5. Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutics
6. Neuromyelitis Optica Spectrum Disorder Late Stage Products (Phase II/III)
7. Neuromyelitis Optica Spectrum Disorder Mid Stage Products (Phase II)
8. Neuromyelitis Optica Spectrum Disorder Early Stage Products (Phase I)
9. Neuromyelitis Optica Spectrum Disorder Preclinical Stage Products
10. Neuromyelitis Optica Spectrum Disorder Therapeutics Assessment
11. Neuromyelitis Optica Spectrum Disorder Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Neuromyelitis Optica Spectrum Disorder Key Companies
14. Neuromyelitis Optica Spectrum Disorder Key Products
15. Neuromyelitis Optica Spectrum Disorder Unmet Needs
16 . Neuromyelitis Optica Spectrum Disorder Market Drivers and Barriers
17. Neuromyelitis Optica Spectrum Disorder Future Perspectives and Conclusion
18. Neuromyelitis Optica Spectrum Disorder Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Neuromyelitis Optica Spectrum Disorder Market
https://www.delveinsight.com/report-store/neuromyelitis-optica-spectrum-disorder-nmosd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Neuromyelitis Optica Spectrum Disorder Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Neuromyelitis Optica Spectrum Disorder Epidemiology
https://www.delveinsight.com/report-store/neuromyelitis-optica-spectrum-disorder-nmosd-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Neuromyelitis Optica Spectrum Disorder Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Patient Monitoring Devices Market https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028.

Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr
Ventricular Assist Devices Market By Product Type (Left Ventricular Assist Devices, Right Ventricular Assist Devices, And Biventricular Assist Devices), By Application Type (Bridge-To-Transplant [Btt], Destination Therapy, And Others), By Design Type (Transcutaneous Ventricular Assist Devcies And Implantable Ventricular Assist Devices), By Type Of Flow (Pulsatile Flow And Continous Flow), By End User (Hospital And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2028.

Resorbable Vascular Scaffolds Market https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr
DelveInsight's 'Resorbable Vascular Scaffolds - Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=reportstore&utm_medium=promotion&utm_campaign=gpr
DelveInsight's 'Vein Illumination Devices - Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Protein Supplements Market
https://www.delveinsight.com/report-store/protein-supplements-market
Protein Supplements Market By Source (Animal-Based [Whey, Casein, Fish, Eggs, Others], Plant-Based [Soy, Rice, Pea, Spirulina, Others]), By Product Type (Protein Powders, Protein Bars, Ready-To-Drink, And Others), By Application (Sports Nutrition And Functional Foods), By Distribution Channel (Supermarkets And Hypermarkets, E-Commerce, Direct-To-Consumer, Others), by geography is estimated to register growth at a remarkable CAGR forecast during 2022-2027 owing to the growing consumer awareness of having a protein rich diet,

Proteomics Market
https://www.delveinsight.com/report-store/prostate-cancer-market-insight
Proteomics Market By Product & Services (Instrumentation Technology [Spectroscopy, Chromatography, Electrophoresis, Protein Microarrays, X-Ray Crystallography, And Other], Reagents & Consumables, And Software & Services), By Application (Clinical Diagnostics, Drug Discovery, And Others), By End-User (Hospitals, Clinical Laboratories, Pharmaceutical Companies, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2028.

Infrared Thermometer Market
https://www.delveinsight.com/report-store/infrared-thermometer-market
Infrared Thermometer Market By Product Type (Contact Thermometers And Non-Contact Thermometers), By End-User (Food And Beverage Industry, Electronic Industry, Healthcare Industry, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2028 owing to the growing need for robust temperature measuring devices in critical industries and rise in the number of infectious diseases across the globe.

Hemoglobinopathies Market
https://www.delveinsight.com/report-store/sport-nutrition-market
Hemoglobinopathies Market By Indication (Thalassemia, Sickle Cell Anaemia, And Others), By Treatment (Stem Cell Therapy, Blood Transfusion, Iron Chelation Therapy, And Others), and by geography is expected to advance at a respectable CAGR forecast till 2027 owing to the increasing prevalence of various hemoglobin disorders and the increasing research & developmental activities concerning to the hemoglobinopathies across the globe

Sport Nutrition Market
https://www.delveinsight.com/report-store/sport-nutrition-market
The Sports Nutrition Market By Product Type (Sports Drinks And Sports Supplements), By Distribution Channels (Hypermarkets & Supermarkets, E-Commerce, And Others), and by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing inclination toward following healthy and active lifestyle and growing importance of sports nutrition among athletes and sportspersons.

Endodontic Devices Market
https://www.delveinsight.com/report-store/endodontic-devices-market
Endodontic Devices Market By Product Type (Instruments [Apex Locators, Endodontic Motors, Endodontic Scalers, Endodontic Lasers, Handpieces, Machine-Assisted Obturation Systems, And Others], Consumables [Obturation, Access Cavity Preparation, Shaping And Cleaning]), By End-User (Dental Hospitals, Dental Clinics, And Others), and by geography is estimated to register growth at a remarkable CAGR during the forecast period from 2023-2028 owing to the rising patient pool associated with dental disorders, poor oral health, leading to increased number of root canal treatments, the increasing population opting for dental aesthetics, among others across the globe.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.